The ACR will be working with the Senate as they consider and debate the important healthcare policies contained in this massive legislation.
Anti-SAE Identifies a Subtype of Dermatomyositis
Albayda et al. describes a North American cohort of patients with dermatomyositis, reporting that small ubiquitin-like modifier activating enzyme (SAE) autoantibodies are clearly associated with this clinical disease. Patients with this clinical phenotype most commonly present with a rash first, followed by muscle involvement.
Updates on ACR Gout Guideline, FDA’s Febuxostat Warning & Pegloticase Therapy
A presentation at ACR Convergence 2021 discussed the 2020 ACR Guideline for the Management of Gout, the latest information on the risk of cardiovascular death associated with febuxostat and the use of pegloticase for patients with gout.
Top 12: Research in Systemic Lupus Erythematosus at a Glance
Dr. Pisetsky’s picks for the top research in lupus presented at ACR Convergence 2021.
Extreme & Uncontrollable Circumstances Policy Will Apply to All MIPS-Eligible Clinicians 2021
The final rule, issued Nov. 2, finalizes many proposed policies, including a decreased conversion factor, billing for shared visits and teaching services, continuation of telehealth services and inclusion of an ACR-led Merit-Based Incentive Payment System Value Pathway.
ACR Overview of 2022 Medicare Physician Fee Schedule Final Rule
The final rule, issued Nov. 2, finalizes many policies in the July proposed rule, including the decreased conversion factor, billing for shared visits and teaching services, the continuation of telehealth services and inclusion of an ACR-led Merit-Based Incentive Payment System Value Pathway.
Policy Change Made Reality in 2021
After a year marked with rheumatology gains in evaluation and management valuation, as well as quality reporting, ongoing ACR efforts target impending Medicare reimbursement cuts and other practice challenges.
Howard Blumstein, MD, Assumes RheumPAC Chair
“Advocacy is not about bribery. There’s nothing dirty about advocating for your patients and the future of your profession in terms of workforce, therapeutic advances and the financial viability of our practices. It’s our duty to do this,” he says. In his new role as the RheumPAC chair, he wants to help ACR/ARP members “see how vital these activities are to the success of our profession.”
FDA Approves First Interchangeable Biosimilar to Adalimumab, Plus a Combination Drug Approved
Cyltezo (adalimumab-adbm) may be interchanged for Humira (adalimumab) for all indications, according to an October decison by the FDA. The FDA has also approved a new combination of celecoxib and tramadol for pain management.
Tumor Necrosis Factor Inhibitors May Slow the Progression of Spondyloarthritis
Recent research indicates tumor necrosis factor inhibitors may slow disease progression in the spine of patients with axial spondyloarthritis.
- « Previous Page
- 1
- …
- 113
- 114
- 115
- 116
- 117
- …
- 805
- Next Page »